Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for ALK-positive non-small cell lung cancer.
‘Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076) in patients with ALK-positive NSCLC who had complete tumor resection,’ the FDA said.
Ken Culver of ALK Positive, a patient and caregiver advocacy group in the US, said in a statement reported in MedPage Today, that: ‘The approval of Alecensa [alectinib] marks a pivotal moment for people newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy.’
‘With this significant advance, it is more important than ever that all patients diagnosed with early-stage lung cancer undergo testing for ALK and other recommended biomarkers to receive the treatment most appropriate for them.’
You can read more about this development here on the FDA website: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer
#LungCancer #treatment #Alecensa #alectinib #LuCE #LungCancerEurope #LungCancer #LungCancerNews #LCSM #FDA #FDAApproval
![Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for ALK-positive non-small cell lung cancer.
‘Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076) in patients with ALK-positive NSCLC who had complete tumor resection,’ the FDA said.
Ken Culver of ALK Positive, a patient and caregiver advocacy group in the US, said in a statement reported in MedPage Today, that: ‘The approval of Alecensa [alectinib] marks a pivotal moment for people newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy.’
‘With this significant advance, it is more important than ever that all patients diagnosed with early-stage lung cancer undergo testing for ALK and other recommended biomarkers to receive the treatment most appropriate for them.’
You can read more about this development here on the FDA website: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer
#LungCancer #treatment #Alecensa #alectinib #LuCE #LungCancerEurope #LungCancer #LungCancerNews #LCSM #FDA #FDAApproval](https://rehearse.lungcancereurope.eu/wp-content/plugins/instagram-feed-pro/img/placeholder.png)
Some positive news last week when the U.S. Food and Drug Administration (FDA) approved alectinib as an adjuvant treatment for ALK-positive non-small cell lung cancer.
‘Efficacy was demonstrated in a global, randomized, open-label trial (ALINA, NCT03456076) in patients with ALK-positive NSCLC who had complete tumor resection,’ the FDA said.
Ken Culver of ALK Positive, a patient and caregiver advocacy group in the US, said in a statement reported in MedPage Today, that: ‘The approval of Alecensa [alectinib] marks a pivotal moment for people newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy.’
‘With this significant advance, it is more important than ever that all patients diagnosed with early-stage lung cancer undergo testing for ALK and other recommended biomarkers to receive the treatment most appropriate for them.’
You can read more about this development here on the FDA website: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer
#LungCancer #treatment #Alecensa #alectinib #LuCE #LungCancerEurope #LungCancer #LungCancerNews #LCSM #FDA #FDAApproval
On April 18th, the Foro Español de Pacientes (Spanish Patient Forum) held its VIII National Meeting in Madrid, an event that brought together healthcare professionals, policymakers and patient advocates to discuss the future of health policies in the EU.
Alfonso Aguarón, Policy Officer at Lung Cancer Europe (LuCE), was among the participants, contributing to a roundtable discussion focused on the impact of future health policies on patients and caregivers.
The meeting, which featured a series of presentations and discussions, aimed to provide a comprehensive platform for stakeholders to voice concerns and propose solutions to the challenges faced by the healthcare system in Spain and across Europe.
The insights provided by LuCE emphasized the need for policies that are not only inclusive but also responsive to the needs of patients and their families. The discussions highlighted several key issues, including the importance of integrating patient perspectives in healthcare decision-making and the need for more robust support systems for caregivers.
The event also served as a call to action for policymakers to consider the practical implications of their decisions on the day-to-day lives of patients and their beloved ones. By bringing together a diverse group of stakeholders, the forum aimed to foster a more collaborative approach to healthcare reform, one that is informed by the firsthand experiences of those most affected by such policies.
Looking ahead, the insights and recommendations gathered during the roundtable discussion are expected to influence ongoing and future health policy developments. The forum’s collaborative approach and its emphasis on inclusive dialogue set a positive precedent for how healthcare challenges should be addressed moving forward.
#ForoEspañoldePacientes #ForoEspanoldePacientes #FEP #FEP24 #FEP2024 #SpanishPatientForum #PatientForum #PatientAdvocacy #healthpolicy #EUHealthPolicy #Advocacy #patientcare #Advocacy #LuCE #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM
On April 18th, the Foro Español de Pacientes (Spanish Patient Forum) held its VIII National Meeting in Madrid, an event that brought together healthcare professionals, policymakers and patient advocates to discuss the future of health policies in the EU.
Alfonso Aguarón, Policy Officer at Lung Cancer Europe (LuCE), was among the participants, contributing to a roundtable discussion focused on the impact of future health policies on patients and caregivers.
The meeting, which featured a series of presentations and discussions, aimed to provide a comprehensive platform for stakeholders to voice concerns and propose solutions to the challenges faced by the healthcare system in Spain and across Europe.
The insights provided by LuCE emphasized the need for policies that are not only inclusive but also responsive to the needs of patients and their families. The discussions highlighted several key issues, including the importance of integrating patient perspectives in healthcare decision-making and the need for more robust support systems for caregivers.
The event also served as a call to action for policymakers to consider the practical implications of their decisions on the day-to-day lives of patients and their beloved ones. By bringing together a diverse group of stakeholders, the forum aimed to foster a more collaborative approach to healthcare reform, one that is informed by the firsthand experiences of those most affected by such policies.
Looking ahead, the insights and recommendations gathered during the roundtable discussion are expected to influence ongoing and future health policy developments. The forum’s collaborative approach and its emphasis on inclusive dialogue set a positive precedent for how healthcare challenges should be addressed moving forward.
#ForoEspañoldePacientes #ForoEspanoldePacientes #FEP #FEP24 #FEP2024 #SpanishPatientForum #PatientForum #PatientAdvocacy #healthpolicy #EUHealthPolicy #Advocacy #patientcare #Advocacy #LuCE #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM
We’re delighted to welcome five new member organizations to our growing Lung Cancer Europe (LuCE) network.
These organisations and their members are essential to delivering our mission and what we do at LuCE, as we work together to strengthen and amplify the lung cancer voice for those impacted by the disease across Europe.
The new organisations are:
ALK FRANCE Cancer Poumon (France)
A group of patients affected by lung cancer in non-smoking populations with ALK+, ROS1 gene mutations and other rare mutations. It aims to raise awareness of their cause and encourage research into mutations to discover new treatments.
https://alkros1francecancerpoumon.wordpress.com/
ALK Positive Europe (Germany)
ALK Positive Europe e.V. (APEU) is a non-profit organisation that connects ALK-positive patient associations, advocacy groups and ALK+ ambassadors across Europe. APEU aims to improve the quality of life for ALK-positive patients and turn an incurable disease into a chronic and hopefully curable disease.
https://alkpositiveeurope.org/
Association of Patients with Respiratory Failure and Lung Transplantation (Bulgaria)
The Association of Patients with Respiratory Failure and Lung Transplantation (APRFLT) was founded in Sofia, Bulgaria in 2017. Its aim is to work for organ donations and transplantations – including lung transplants – in Bulgaria.
Website: Under construction
Lung Cancer Patient Association Punim Plucima (Serbia )
One of the most active patient organisations in Serbia, its main goal is to improve status for lung cancer patients, including new treatments and faster diagnostics.
https://www.punimplucima.rs/
Oncogene Cancer Research (UK)
Oncogene Cancer Research is funding medical research to extend the lives of people with oncogene-driven lung cancers.
https://www.oncogeneresearch.org/
LuCE is proud to welcome these new members and we will profile them in more detail in the coming weeks.
If your organization would like to become a member LuCE, please get in touch with our team through the CONTACT page on our website: https://www.lungcancereurope.eu/contact-us/
#Members #NewMembers #LuCE #LungCancerEurope #LungCancer #LCSM #LungCancerPatientAdvocacy #LuCEMembers
We’re delighted to welcome five new member organizations to our growing Lung Cancer Europe (LuCE) network.
These organisations and their members are essential to delivering our mission and what we do at LuCE, as we work together to strengthen and amplify the lung cancer voice for those impacted by the disease across Europe.
The new organisations are:
ALK FRANCE Cancer Poumon (France)
A group of patients affected by lung cancer in non-smoking populations with ALK+, ROS1 gene mutations and other rare mutations. It aims to raise awareness of their cause and encourage research into mutations to discover new treatments.
https://alkros1francecancerpoumon.wordpress.com/
ALK Positive Europe (Germany)
ALK Positive Europe e.V. (APEU) is a non-profit organisation that connects ALK-positive patient associations, advocacy groups and ALK+ ambassadors across Europe. APEU aims to improve the quality of life for ALK-positive patients and turn an incurable disease into a chronic and hopefully curable disease.
https://alkpositiveeurope.org/
Association of Patients with Respiratory Failure and Lung Transplantation (Bulgaria)
The Association of Patients with Respiratory Failure and Lung Transplantation (APRFLT) was founded in Sofia, Bulgaria in 2017. Its aim is to work for organ donations and transplantations – including lung transplants – in Bulgaria.
Website: Under construction
Lung Cancer Patient Association Punim Plucima (Serbia )
One of the most active patient organisations in Serbia, its main goal is to improve status for lung cancer patients, including new treatments and faster diagnostics.
https://www.punimplucima.rs/
Oncogene Cancer Research (UK)
Oncogene Cancer Research is funding medical research to extend the lives of people with oncogene-driven lung cancers.
https://www.oncogeneresearch.org/
LuCE is proud to welcome these new members and we will profile them in more detail in the coming weeks.
If your organization would like to become a member LuCE, please get in touch with our team through the CONTACT page on our website: https://www.lungcancereurope.eu/contact-us/
#Members #NewMembers #LuCE #LungCancerEurope #LungCancer #LCSM #LungCancerPatientAdvocacy #LuCEMembers
We love this photo! Take a look at LuCE members, staff and supporters who attended our AGM in Zagreb. It was a very positive and informative event. We extend our thanks to all attendees and all of you!
We look forward to another productive year ahead and to AGM 2025.
#LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM #Zagreb #Zagreb24 #Zagreb2024
We love this photo! Take a look at LuCE members, staff and supporters who attended our AGM in Zagreb. It was a very positive and informative event. We extend our thanks to all attendees and all of you!
We look forward to another productive year ahead and to AGM 2025.
#LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM #Zagreb #Zagreb24 #Zagreb2024
The winners of the LuCE Advocacy Awards for 2024 were announced at the AGM in Zagreb by LuCE President Anne-Marie Baird. These awards recognise the contribution of individuals and organisations to lung cancer awareness and advocacy.
The LuCE Awareness Award category recognises what members are doing locally to help the lung cancer community and was won by AEACaP, the Asociación Española de Afectados de Cáncer de Pulmón, for their Activate Project.
The LuCE Advocacy Award recognises individuals for truly making a difference to the lung cancer communities through their advocacy work and was won by Diego Villalón of Fundación MÁS QUE IDEAS.
Huge congratulations to both category winners and thank you for the invaluable work you do to increase lung cancer awareness.
#LuCEAwards #Awards #AwarenessAward #Awareness #Advocacy #AdvocacyAward #LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM
The winners of the LuCE Advocacy Awards for 2024 were announced at the AGM in Zagreb by LuCE President Anne-Marie Baird. These awards recognise the contribution of individuals and organisations to lung cancer awareness and advocacy.
The LuCE Awareness Award category recognises what members are doing locally to help the lung cancer community and was won by AEACaP, the Asociación Española de Afectados de Cáncer de Pulmón, for their Activate Project.
The LuCE Advocacy Award recognises individuals for truly making a difference to the lung cancer communities through their advocacy work and was won by Diego Villalón of Fundación MÁS QUE IDEAS.
Huge congratulations to both category winners and thank you for the invaluable work you do to increase lung cancer awareness.
#LuCEAwards #Awards #AwarenessAward #Awareness #Advocacy #AdvocacyAward #LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM
Last weekend LuCE hosted a very productive AGM and General Assembly in Zagreb. We were delighted to see some new members elected to the Board of Lung Cancer Europe.
We also had a variety of excellent educational presentations:
➡️ LuCE President Anne-Marie Baird presented on ‘New technologies and therapies in lung cancer’
➡️ Sarah Geraghty of The Communications Clinic on the ‘Importance of Communication’,
➡️ Ivana Stracenski of J&J Innovative Medicine on ‘Orphan Drug Designation’ and
➡️ ‘Updates from the EU’ by LuCE Policy Officer Alfonso Aguarón.
There were also emotional moments as Vice-President Ewelina Szmytke’s mandate came to an end . . . and happier times too as we got to reunite with members.
We would again like to thank all those who contributed to making this such a successful event – including our speakers, our members, LuCE staff, our supporters and all the team in Zagreb.
Thank you.
#LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM #Zagreb #Zagreb24 #Zagreb2024
Last weekend LuCE hosted a very productive AGM and General Assembly in Zagreb. We were delighted to see some new members elected to the Board of Lung Cancer Europe.
We also had a variety of excellent educational presentations:
➡️ LuCE President Anne-Marie Baird presented on ‘New technologies and therapies in lung cancer’
➡️ Sarah Geraghty of The Communications Clinic on the ‘Importance of Communication’,
➡️ Ivana Stracenski of J&J Innovative Medicine on ‘Orphan Drug Designation’ and
➡️ ‘Updates from the EU’ by LuCE Policy Officer Alfonso Aguarón.
There were also emotional moments as Vice-President Ewelina Szmytke’s mandate came to an end . . . and happier times too as we got to reunite with members.
We would again like to thank all those who contributed to making this such a successful event – including our speakers, our members, LuCE staff, our supporters and all the team in Zagreb.
Thank you.
#LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM #Zagreb #Zagreb24 #Zagreb2024
We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last weekend:
➡️ President: Anne Marie Baird, Ireland – Sitting Board Member
➡️ Vice President: Debra Montague, @alkpositivelungcanceruk, UK – Re-elected
➡️ Treasurer: Alexandre Brutti, @patientsenreseau/Mon Reseau Cancer du Poumon, France – New Board Member
➡️ Board Member: Lavinia Magee, Lung Cancer Nursing UK (LCNUK), UK – Re-elected
➡️ Board Member: Annette Hans, Landesverband Baden-Württemberg für Lungenkrebskranke und deren Angehörige e.V, Germany – Sitting Board Member
➡️ Board Member: Erika Pataki, @lelekzetegyesulet, Hungary – Sitting Board Member
➡️ Board Member: Angeliki Souri, @fairlifelcc, Greece – New Board Member
Anne-Marie Baird’s mandate as President has been extended for one additional year.
We would like to thank the outgoing Board for all their hard work over the past year and very much look forward to working with the new Board.
Please note that Angeliki Souri is not in attached photo.
#Board #NewBoard #elections #LuCE #LuCEAGM #AGM #LuCEBoard #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LCSM
We are delighted to announce the new Board of Lung Cancer Europe (LuCE) elected at our AGM in Zagreb last weekend:
➡️ President: Anne Marie Baird, Ireland – Sitting Board Member
➡️ Vice President: Debra Montague, @alkpositivelungcanceruk, UK – Re-elected
➡️ Treasurer: Alexandre Brutti, @patientsenreseau/Mon Reseau Cancer du Poumon, France – New Board Member
➡️ Board Member: Lavinia Magee, Lung Cancer Nursing UK (LCNUK), UK – Re-elected
➡️ Board Member: Annette Hans, Landesverband Baden-Württemberg für Lungenkrebskranke und deren Angehörige e.V, Germany – Sitting Board Member
➡️ Board Member: Erika Pataki, @lelekzetegyesulet, Hungary – Sitting Board Member
➡️ Board Member: Angeliki Souri, @fairlifelcc, Greece – New Board Member
Anne-Marie Baird’s mandate as President has been extended for one additional year.
We would like to thank the outgoing Board for all their hard work over the past year and very much look forward to working with the new Board.
Please note that Angeliki Souri is not in attached photo.
#Board #NewBoard #elections #LuCE #LuCEAGM #AGM #LuCEBoard #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LCSM
We are preparing to leave Zagreb today following a very busy two days at the LuCE AGM.
We will update members in the coming days about this highly informative and productive event – including, of course, details of the newly elected Board of Lung Cancer Europe.
We would like to take this opportunity to thank all those who contributed to making this such a successful event – including our speakers, our members, LuCE staff, our supporters and all in Zagreb.
Thank you.
#LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM #Zagreb #Zagreb24 #Zagreb2024
We are preparing to leave Zagreb today following a very busy two days at the LuCE AGM.
We will update members in the coming days about this highly informative and productive event – including, of course, details of the newly elected Board of Lung Cancer Europe.
We would like to take this opportunity to thank all those who contributed to making this such a successful event – including our speakers, our members, LuCE staff, our supporters and all in Zagreb.
Thank you.
#LuCE #LuCEAGM #AGM #LuCE24 #LuCEAGM2024 #LungCancerEurope #LungCancer #LungCancerPatientAdvocacy #LCSM #Zagreb #Zagreb24 #Zagreb2024
Keep Up-to-Date
Find out more about the latest news and events from Lung Cancer Europe.
No more posts